ClinicalTrials.gg
RecruitingNCT07094724Updated Aug 26, 2025

High-Titer Neutralizing Plasma for West Nile Fever in Hospitalized Patients

A Phase 2 interventional study of Plasma in West Nile Fever, sponsored by Gili Regev-Yochay MD. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Gili Regev-Yochay MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will test whether plasma containing high levels of neturalizing antibodies against West Nile virus (WNV) can help people hospitalized with severe West Nile fever recover faster and avoid serious complications. West Nile virus is spread by mosquitoes and can cause mild flu-like symptoms or, in severe cases, brain infections. Currently, there is no specific medication to treat the infection, and doctors primarily provide supportive care.

In this study, patients who are sick enough to require hospitalization will receive plasma donated by people who have recovered from West Nile virus and developed high titer neutralizing antibodies against the disease. Researchers will closely monitor these patients to see how quickly their symptoms improve and whether the plasma helps reduce the risk of death or shorten hospital stays.

To evaluate how well the plasma works, researchers will compare these patients to others who were infected in the past for West Nile virus but did not receive plasma. The study will also examine whether the plasma is safe to use and whether it causes any side effects.

Through this research, scientists hope to determine if antibody-rich plasma could become a helpful treatment option for people with severe West Nile virus infections.

02

Conditions studied

  • West Nile Fever

Keywords

  • West Nile Fever
  • plasma
  • neuroinvasive WN disease
03

In context

Lead sponsor

This is the only study on the registry with Gili Regev-Yochay MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults hospitalized due to WNF, confirmed by a positive IgM or PCR result in blood or cerebrospinal fluid (CSF).
  • Symptomatic acute illness, including fever and/or neurological manifestations (headache, somnolence, confusion, seizures, personality changes, extra-pyramidal manifestations, cranial nerve palsies, etc.).
  • No more than 72 hours have elapsed since collection of diagnostic sample.
  • Age criteria

    • Age ≥60 years OR
    • Age 18-59 years with previously documented , including hypogammaglobulinemia, treatment with anti-CD20 agents during the last 12 months, hematologic , bone marrow transplantation, solid organ transplantation, acquired immunodeficiency syndrome (AIDS), or severe primary immunodeficiency.

Exclusion criteria

Exclusion Criteria:

  • Age \<60 years without significant .
  • More than 72 hours have elapsed since collection of diagnostic sample.
  • Pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    WN-neutralizing Plasma

    IV plasma

    Biological: Plasma

  • No intervention
    historical untreated control

Interventions

06

What researchers measure

Primary outcomes

  1. All-cause mortality within 30 days post enrollment.

    Time frame: 0-30 days

Secondary outcomes

  1. MMSE score at enrollment and at 30 (±3) days post enrollment

    Time frame: 0-33 days

  2. Discharge to pre-hospitalization residence setting.

    Patients who were discharged to their pre-hospitalization residence setting will be coded "1"; Patients who were discharged to another setting (e.g., rehabilitation facility) will be coded "0".

    Time frame: 0-90 days.

  3. Length of hospital stay

    Time frame: 0-90 days.

  4. Serum WNV PCR, IgG, IgM, IgA and neutralizing antibody levels at enrollment, at 7 (±3) days (if still hospitalized), and 30 (±3) days post enrollment.

    Time frame: 0-33 days

  5. WNV PCR, IgG, IgM, IgA and neutralizing antibodies levels in the CSF, at enrollment and within 48-72 (±48) hours post enrollment.

    Time frame: 0-7 days

  6. Serum will be kept for further assessment of additional immunological indices and markers of inflammation.

    Time frame: 10 years.

  7. Peripheral Blood Mononuclear Cell (PBMC) collection at enrollment, at 14 (±3) days (if still hospitalized), and at 30 (±3) days post enrollment.

    Time frame: 0-33 days

  8. Change in Barthel Index at 30 (±3) days post enrollment, compared to baseline.

    Time frame: 0-33 days.

  9. Change in GCS score at 30 (±3) days post enrollment, compared to enrollment.

    Time frame: 0-33 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PubMed 3558716 ↗
  • Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol. 2014 Aug;13(8):844-54. doi: 10.1016/S1474-4422(14)70120-6. PubMed 25030516 ↗
  • Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud. 1988;10(2):64-7. doi: 10.3109/09638288809164105. PubMed 3042746 ↗
  • Norris D, Clark MS, Shipley S. The Mental Status Examination. Am Fam Physician. 2016 Oct 15;94(8):635-641. PubMed 27929229 ↗
  • Katzenellenbogen G, Canetti M, Margalit I, Shusterman Y, Simchovitz-Gesher A, Naveh L, Baharav N, Goldenfeld M, Belkin A, Brod M, Wieder-Finesod A, Leshem E, Magiel E, Levy I, Lustig Y, Indenbaum V, Maggio N, Dekel S, Mechnik B, Peretz Y, Barda N, Tafesh A, Yahav D, Regev-Yochay G. West Nile Virus Outbreak in Israel 2024 Compared with Previous Seasons: A Retrospective Study. Infect Dis Ther. 2025 Jul;14(7):1405-1415. doi: 10.1007/s40121-025-01140-3. Epub 2025 Apr 3. PubMed 40180788 ↗
  • Popescu CP, Florescu SA, Hasbun R, Harxhi A, Evendar R, Kahraman H, Neuberger A, Codreanu D, Zaharia MF, Tosun S, Ceausu E, Ruta SM, Dragovac G, Pshenichnaya N, Gopatsa G, Shmaylenko O, Nagy E, Malbasa JD, Strbac M, Pandak N, Pullukcu H, Lakatos B, Cag Y, Cascio A, Coledan I, Oncu S, Erdem H. Prediction of unfavorable outcomes in West Nile virus neuroinvasive infection - Result of a multinational ID-IRI study. J Clin Virol. 2020 Jan;122:104213. doi: 10.1016/j.jcv.2019.104213. Epub 2019 Nov 11. PubMed 31778945 ↗
  • Roberts JA, Kim CY, Hwang SA, Hassan A, Covington E, Heydari K, Lyerly M, Sejvar JJ, Hasbun R, Prasad M, Thakur KT. Clinical, Prognostic, and Longitudinal Functional and Neuropsychological Features of West Nile Virus Neuroinvasive Disease in the United States: A Systematic Review and Meta-Analysis. Ann Neurol. 2025 Jul;98(1):93-106. doi: 10.1002/ana.27220. Epub 2025 Feb 26. PubMed 40008684 ↗
  • Chancey C, Grinev A, Volkova E, Rios M. The global ecology and epidemiology of West Nile virus. Biomed Res Int. 2015;2015:376230. doi: 10.1155/2015/376230. Epub 2015 Mar 19. PubMed 25866777 ↗
  • Moirano G, Fletcher C, Semenza JC, Lowe R. Short-term effect of temperature and precipitation on the incidence of West Nile Neuroinvasive Disease in Europe: a multi-country case-crossover analysis. Lancet Reg Health Eur. 2024 Dec 4;48:101149. doi: 10.1016/j.lanepe.2024.101149. eCollection 2025 Jan. PubMed 39717226 ↗
  • Erazo D, Grant L, Ghisbain G, Marini G, Colon-Gonzalez FJ, Wint W, Rizzoli A, Van Bortel W, Vogels CBF, Grubaugh ND, Mengel M, Frieler K, Thiery W, Dellicour S. Contribution of climate change to the spatial expansion of West Nile virus in Europe. Nat Commun. 2024 Feb 8;15(1):1196. doi: 10.1038/s41467-024-45290-3. PubMed 38331945 ↗

Individual participant data

Plan to share: Yes — deidentified data will be available by a reasonable request to the PI, after publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Upon publication.

Access criteria: PI \& CRA

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2025, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 30, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07094724
Lead sponsor
Gili Regev-Yochay MD
Responsible party
Gili Regev-Yochay MD (Director of the Sheba Pandemic Preparedness Research Institute (SPRI), Sheba Medical Center) — Sponsor-investigator
First posted
Jul 30, 2025
Start date
Jul 30, 2025
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Aug 26, 2025

Study contacts

Gili Regev-Yochay, MD
Contact
gili.regev@sheba.health.gov.il
+972526666197
Almog Cohen-Huszti
Contact
Almog.CohenHuszti@sheba.health.gov.il
+972545377537
Gili Regev-Yochay, MD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human plasma

Start the discussion